Mozart Therapeutics Announces Oral Presentation on MTX-101 at the 2024 American Diabetes Association’s 84th Scientific Sessions

Posted on by

Data highlight potential of first-in-class CD8 Treg modulator Phase 1 clinical trial underway to evaluate MTX-101 in healthy adults and patients with celiac disease or type 1 diabetes SEATTLE, June 21, 2024 /PRNewswire/ — Mozart Therapeutics, a clinical stage biopharmaceutical company…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.